Data from Pivotal KEYNOTE-087 Trial Show
Overall Response Rate (ORR) of 69.0 Percent and Complete Remission
Rate (CRR) of 22.4 Percent
With More than Two Years of Follow-up,
Findings from KEYNOTE-013 Show ORR of 58 Percent and CRR of 19
Percent with Responses of 12 Months or Greater in 70 Percent of
Responding Patients
Merck (NYSE:MRK), known as MSD outside the United States and
Canada, announced today updated findings evaluating KEYTRUDA®
(pembrolizumab), the company’s anti-PD-1 therapy, in two trials of
patients with relapsed or refractory classical Hodgkin lymphoma
(cHL). In the KEYNOTE-087 and KEYNOTE-013 trials, KEYTRUDA
demonstrated overall response rates (ORR) of 69.0 percent and 58
percent, respectively. KEYNOTE-013, which had a median follow up of
29 months, showed responses of 12 months or greater in 70 percent
of patients who responded to therapy. These findings will be
presented today at the 58th Annual Meeting of the American Society
of Hematology (ASH). Additionally, data from these trials supported
the recently announced regulatory filing with the U.S. Food and
Drug Administration.
“As the data mature from these two studies, we continue to be
encouraged by the response rates, including complete remission and
durable responses, in patients with relapsed or refractory
classical Hodgkin lymphoma,” said Dr. Roger Dansey, senior vice
president and therapeutic area head, oncology late-stage
development, Merck Research Laboratories.
The KEYTRUDA clinical development program includes more than 30
tumor types in nearly 400 clinical trials, including more than 200
trials that combine KEYTRUDA with other cancer treatments. For
hematologic malignancies specifically, Merck is conducting broad
immuno-oncology research assessing the role of monotherapy and
combination regimens with KEYTRUDA (pembrolizumab). The hematology
program includes nearly 40 ongoing studies – including company
sponsored, investigator sponsored and collaborative studies;
several of these are registration-enabling trials.
“When patients with classical Hodgkin lymphoma do not respond to
standard of care chemotherapy or autologous stem
cell transplantation, the cancer is difficult to successfully
treat. For these patients, who are often in their 20s and 30s, the
need to identify new treatment options is urgent,” said Dr. Craig
Moskowitz, clinical director, division of hematologic oncology,
Memorial Sloan Kettering Cancer Center. “These data are promising
and show that pembrolizumab may provide meaningful clinical benefit
to patients with this disease.”
Results from KEYNOTE-087
Results from the KEYNOTE-087 trial will be presented in an oral
presentation by Dr. Moskowitz at 5 p.m. PST (Location: San Diego
Convention Center, Room 6B) (Abstract #1107).
KEYNOTE-087 is a multicenter, open-label, multi-cohort,
activity-estimating phase 2 trial evaluating KEYTRUDA (200 mg fixed
dose every three weeks) monotherapy in patients with relapsed or
refractory cHL across three cohorts. The primary endpoints include
overall safety, tolerability, and ORR (per blinded independent
central review, BICR); secondary endpoints include ORR (per
investigator review), duration of response (DOR), progression-free
survival (PFS) and overall survival (OS). The patient cohorts are
intended to assess the outcome measures in: patients whose disease
progressed following an autologous stem cell transplantation and
subsequent treatment with brentuximab vedotin, an antibody drug
conjugate (Cohort 1); patients who failed salvage chemotherapy and
were ineligible for a transplant and whose disease progressed
following treatment with brentuximab vedotin (Cohort 2); and
patients whose disease progressed after transplant and who did not
receive brentuximab vedotin after transplant (Cohort 3).
Across all 210 enrolled patients, the ORR was 69.0 percent
(n=145; 95% CI, 62.3-75.2) by BICR, and the complete remission rate
was 22.4 percent (n=47; 95% CI, 16.9-28.6). Across all cohorts, 93
percent of patients experienced a decrease in tumor burden
(n=192).
By cohort, the data showed:
- In Cohort 1, (n=69), ORR was 73.9
percent (n=51; 95% CI, 61.9-83.7) – with complete remissions in
21.7 percent (n=15; 95% CI, 12.7-33.3) and partial remissions in
52.2 percent (n=36; 95% CI, 39.8-64.4) of patients. An additional
15.9 percent of patients had stable disease (n=11; 95% CI,
8.2-26.7) and 7.2 percent of patients had progressive disease (n=5;
95% CI, 2.4-16.1). Additionally, 82.2 percent of responding
patients had a response of six months or greater.
- In Cohort 2 (n=81), ORR was 64.2
percent (n=52; 95% CI, 52.8-74.6) – with complete remissions in
24.7 percent (n=20; 95% CI, 15.8-35.5) and partial remissions in
39.5 percent (n=32; 95% CI, 28.8-51.0) of patients. An additional
12.3 percent of patients had stable disease (n=10; 95% CI,
6.1-21.5) and 21.0 percent of patients had progressive disease
(n=17; 95% CI, 12.7-31.5). Additionally, 70 percent of responding
patients had a response of six months or greater.
- In Cohort 3 (n=60), ORR was 70.0
percent (n=42; 95% CI, 56.8-81.2) – with complete remissions in
20.0 percent (n=12; 95% CI, 10.8-32.3) and partial remissions in
50.0 percent (n=30; 95% CI, 36.8-63.2) of patients. An additional
16.7 percent of patients had stable disease (n=10; 95% CI,
8.3-28.5) and 13.3 percent of patients had progressive disease
(n=8; 95% CI, 5.9-24.6). Additionally, 75.6 percent of responding
patients had a response of six months or greater.
Results also included an analysis of patients with primary
refractory disease (n=73), defined as failure to achieve complete
or partial response to first-line treatment. In this patient
population, the ORR (per BICR) was 79.5 percent (n=58; 95% CI,
68.4-88.0). Additionally, an ORR of 67.8 percent (95% CI,
59.6-75.3) was reported in patients who relapsed after three or
more lines of prior therapy (n=99/146).
The safety profile of KEYTRUDA (pembrolizumab) was consistent
with that observed in previously reported studies. The most
common treatment-related adverse events were hypothyroidism
(12.4%), pyrexia (10.5%), fatigue (9.0%), rash (7.6%), diarrhea
(7.1%), headache (6.2%), nausea (5.7%), cough (5.7%) and
neutropenia (5.2%). The most common grade 3 or 4 treatment-related
adverse events were neutropenia (2.4%), diarrhea (1.0%) and dyspnea
(1.0%). Immune-mediated adverse events included pneumonitis (2.9%),
hyperthyroidism (2.9%), colitis (1.0%) and myositis (1.0%). There
were nine discontinuations because of treatment-related adverse
events and no treatment-related deaths.
Results from KEYNOTE-013
Results from the KEYNOTE-013 trial will be presented in an oral
presentation by Dr. Philippe Armand, medical oncologist,
Dana-Farber Cancer Institute at 5:15 p.m. PST (Location: San Diego
Convention Center, Room 6B) (Abstract #1108).
KEYNOTE-013 is an ongoing, multicenter, non-randomized, phase 1b
trial of approximately 200 patients evaluating the safety,
tolerability, and efficacy of KEYTRUDA (pembrolizumab) monotherapy
in patients with blood cancers, including myelodysplastic
syndromes, multiple myeloma, classical Hodgkin lymphoma,
mediastinal large B cell lymphoma and certain other non-Hodgkin’s
lymphoma (or lymphomata). The primary endpoints of the study
include overall safety, tolerability, and complete remission rate
(as measured by International Harmonization Project Response
Criteria); secondary endpoints include ORR, DOR, PFS, and OS.
Data from a cohort of the study evaluated KEYTRUDA monotherapy
at 10 mg/kg every two weeks in patients with relapsed or refractory
cHL who had progressed on or after treatment with brentuximab
vedotin after failure of autologous stem cell transplant, or who
were transplant-ineligible. Response was assessed at week 12 and
every 8 weeks thereafter according to the International
Harmonization Project 2007 criteria.
Across all 31 patients enrolled in the KEYNOTE-013 classical
Hodgkin lymphoma cohort, the ORR was 58 percent (n=18; 95% CI,
39-76) by BICR, and the complete remission rate was 19 percent
(n=6; 95% CI, 8-38). Thirty-nine percent of patients achieved
partial remission (n=12; 95% CI, 22-58) and 23 percent had stable
disease (n=7; 95% CI, 10-41). The median duration of response was
not yet reached (range 0.0+ to 26.1+ months) and 70 percent of
responding patients had a response of 12 months or greater. The
median duration of follow-up was 29 months.
Measured by BICR, median PFS was 11.4 months (4.9-27.8). The
six-month PFS rate was 66 percent and the 12-month rate was 48
percent. Median OS was not reached. Six-month and 12-month OS rates
were 100 percent and 87 percent, respectively.
The safety profile of KEYTRUDA was consistent with that observed
in previously reported studies. The most common
treatment-related adverse events were diarrhea (19%),
hypothyroidism (13%), pneumonitis (13%), nausea (13%), fatigue
(10%) and dyspnea (10%). The most common grade 3 or 4
treatment-related adverse events were colitis (3%), axillary pain
(3%), AST increased (3%), joint swelling (3%), nephrotic syndrome
back pain (3%) and dyspnea (3%). Adverse events leading to
discontinuation were nephrotic syndrome (grade 3), interstitial
lung disease (grade 2) and pneumonitis (grade 2). There were no
treatment-related deaths.
About Hodgkin Lymphoma
Hodgkin lymphoma is a type of lymphoma that develops in the
white blood cells, called lymphocytes, which are part of the immune
system. Hodgkin lymphoma can start almost anywhere – most often in
lymph nodes in the upper part of the body, with the most common
sites being in the chest, neck or under the arms. In 2016, it is
estimated that more than 8,500 people will be diagnosed with
Hodgkin lymphoma in the U.S.; cHL accounts for about 95 percent of
all cases of Hodgkin lymphoma in developed countries.
About KEYTRUDA® (pembrolizumab)
KEYTRUDA is a humanized monoclonal antibody that works by
increasing the ability of the body’s immune system to help detect
and fight tumor cells. KEYTRUDA blocks the interaction between PD-1
and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes
which may affect both tumor cells and healthy cells.
KEYTRUDA is administered as an intravenous infusion over 30
minutes every three weeks for the approved indications. KEYTRUDA
for injection is supplied in a 100 mg single use vial.
KEYTRUDA Indications and Dosing
Melanoma
KEYTRUDA is indicated for the treatment of patients with
unresectable or metastatic melanoma at a dose of 2 mg/kg every
three weeks until disease progression or unacceptable toxicity.
Lung Cancer
KEYTRUDA is indicated for the first-line treatment of patients
with metastatic non-small cell lung cancer (NSCLC) whose tumors
have high PD-L1 expression [tumor proportion score (TPS) ≥50%] as
determined by an FDA-approved test, with no EGFR or ALK genomic
tumor aberrations.
KEYTRUDA is also indicated for the treatment of patients with
metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined
by an FDA-approved test, with disease progression on or after
platinum-containing chemotherapy. Patients with EGFR or ALK genomic
tumor aberrations should have disease progression on FDA-approved
therapy for these aberrations prior to receiving KEYTRUDA.
In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of
200 mg every three weeks until disease progression, unacceptable
toxicity, or up to 24 months in patients without disease
progression.
Head and Neck Cancer
KEYTRUDA (pembrolizumab) is indicated for the treatment of
patients with recurrent or metastatic head and neck squamous cell
carcinoma (HNSCC) with disease progression on or after
platinum-containing chemotherapy. This indication is approved under
accelerated approval based on tumor response rate and durability of
response. Continued approval for this indication may be contingent
upon verification and description of clinical benefit in the
confirmatory trials. In HNSCC, KEYTRUDA is administered at a fixed
dose of 200 mg every three weeks until disease progression,
unacceptable toxicity, or up to 24 months in patients without
disease progression.
Selected Important Safety Information for
KEYTRUDA® (pembrolizumab)
KEYTRUDA can cause immune-mediated pneumonitis, including fatal
cases. Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving
KEYTRUDA, including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%),
and 5 (0.1%) pneumonitis, and occurred more frequently in patients
with a history of prior thoracic radiation (6.9%) compared to those
without (2.9%). Monitor patients for signs and symptoms of
pneumonitis. Evaluate suspected pneumonitis with radiographic
imaging. Administer corticosteroids for Grade 2 or greater
pneumonitis. Withhold KEYTRUDA for Grade 2; permanently discontinue
KEYTRUDA for Grade 3 or 4 or recurrent Grade 2 pneumonitis.
KEYTRUDA can cause immune-mediated colitis. Colitis occurred in
48 (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2
(0.4%), 3 (1.1%), and 4 (<0.1%) colitis. Monitor patients for
signs and symptoms of colitis. Administer corticosteroids for Grade
2 or greater colitis. Withhold KEYTRUDA for Grade 2 or 3;
permanently discontinue KEYTRUDA for Grade 4 colitis.
KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred
in 19 (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2
(0.1%), 3 (0.4%), and 4 (<0.1%) hepatitis. Monitor patients for
changes in liver function. Administer corticosteroids for Grade 2
or greater hepatitis and, based on severity of liver enzyme
elevations, withhold or discontinue KEYTRUDA.
KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17
(0.6%) of 2799 patients receiving KEYTRUDA, including Grade 2
(0.2%), 3 (0.3%), and 4 (<0.1%) hypophysitis. Monitor patients
for signs and symptoms of hypophysitis (including hypopituitarism
and adrenal insufficiency). Administer corticosteroids and hormone
replacement as clinically indicated. Withhold KEYTRUDA for Grade 2;
withhold or discontinue for Grade 3 or 4 hypophysitis.
KEYTRUDA (pembrolizumab) can cause thyroid disorders, including
hyperthyroidism, hypothyroidism, and thyroiditis. Hyperthyroidism
occurred in 96 (3.4%) of 2799 patients receiving KEYTRUDA,
including Grade 2 (0.8%) and 3 (0.1%) hyperthyroidism.
Hypothyroidism occurred in 237 (8.5%) of 2799 patients receiving
KEYTRUDA, including Grade 2 (6.2%) and 3 (0.1%) hypothyroidism. The
incidence of new or worsening hypothyroidism was higher in patients
with HNSCC occurring in 28 (15%) of 192 patients with HNSCC,
including Grade 3 (0.5%) hypothyroidism. Thyroiditis occurred in 16
(0.6%) of 2799 patients receiving KEYTRUDA, including Grade 2
(0.3%) thyroiditis. Monitor patients for changes in thyroid
function (at the start of treatment, periodically during treatment,
and as indicated based on clinical evaluation) and for clinical
signs and symptoms of thyroid disorders. Administer replacement
hormones for hypothyroidism and manage hyperthyroidism with
thionamides and beta-blockers as appropriate. Withhold or
discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism.
KEYTRUDA can cause type 1 diabetes mellitus, including diabetic
ketoacidosis, which have been reported in 6 (0.2%) of 2799
patients. Monitor patients for hyperglycemia or other signs and
symptoms of diabetes. Administer insulin for type 1 diabetes, and
withhold KEYTRUDA and administer antihyperglycemics in patients
with severe hyperglycemia.
KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred
in 9 (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2
(0.1%), 3 (0.1%), and 4 (<0.1%) nephritis. Monitor patients for
changes in renal function. Administer corticosteroids for Grade 2
or greater nephritis. Withhold KEYTRUDA for Grade 2; permanently
discontinue KEYTRUDA for Grade 3 or 4 nephritis.
KEYTRUDA can cause other clinically important immune-mediated
adverse reactions. For suspected immune-mediated adverse reactions,
ensure adequate evaluation to confirm etiology or exclude other
causes. Based on the severity of the adverse reaction, withhold
KEYTRUDA and administer corticosteroids. Upon improvement to Grade
1 or less, initiate corticosteroid taper and continue to taper over
at least 1 month. Based on limited data from clinical studies in
patients whose immune-related adverse reactions could not be
controlled with corticosteroid use, administration of other
systemic immunosuppressants can be considered. Resume KEYTRUDA when
the adverse reaction remains at Grade 1 or less following
corticosteroid taper. Permanently discontinue KEYTRUDA for any
Grade 3 immune-mediated adverse reaction that recurs and for any
life-threatening immune-mediated adverse reaction.
The following clinically significant immune-mediated adverse
reactions occurred in less than 1% (unless otherwise indicated) of
2799 patients: arthritis (1.5%), exfoliative dermatitis, bullous
pemphigoid, rash (1.4%), uveitis, myositis, Guillain-Barré
syndrome, myasthenia gravis, vasculitis, pancreatitis, hemolytic
anemia, and partial seizures arising in a patient with inflammatory
foci in brain parenchyma.
KEYTRUDA (pembrolizumab) can cause severe or life-threatening
infusion-related reactions, which have been reported in 6 (0.2%) of
2799 patients. Monitor patients for signs and symptoms of
infusion-related reactions, including rigors, chills, wheezing,
pruritus, flushing, rash, hypotension, hypoxemia, and fever. For
Grade 3 or 4 reactions, stop infusion and permanently discontinue
KEYTRUDA.
Based on its mechanism of action, KEYTRUDA can cause fetal harm
when administered to a pregnant woman. If used during pregnancy, or
if the patient becomes pregnant during treatment, apprise the
patient of the potential hazard to a fetus. Advise females of
reproductive potential to use highly effective contraception during
treatment and for 4 months after the last dose of KEYTRUDA.
In KEYNOTE-006, KEYTRUDA was discontinued due to adverse
reactions in 9% of 555 patients with advanced melanoma; adverse
reactions leading to discontinuation in more than one patient were
colitis (1.4%), autoimmune hepatitis (0.7%), allergic reaction
(0.4%), polyneuropathy (0.4%), and cardiac failure (0.4%). Adverse
reactions leading to interruption of KEYTRUDA occurred in 21% of
patients; the most common (≥1%) was diarrhea (2.5%). The most
common adverse reactions with KEYTRUDA vs ipilimumab were fatigue
(28% vs 28%), diarrhea (26% with KEYTRUDA), rash (24% vs 23%), and
nausea (21% with KEYTRUDA). Corresponding incidence rates are
listed for ipilimumab only for those adverse reactions that
occurred at the same or lower rate than with KEYTRUDA.
In KEYNOTE-002, KEYTRUDA was discontinued due to adverse
reactions in 12% of 357 patients with advanced melanoma; the most
common (≥1%) were general physical health deterioration (1%),
asthenia (1%), dyspnea (1%), pneumonitis (1%), and generalized
edema (1%). Adverse reactions leading to interruption of KEYTRUDA
occurred in 14% of patients; the most common (≥1%) were dyspnea
(1%), diarrhea (1%), and maculopapular rash (1%). The most common
adverse reactions with KEYTRUDA vs chemotherapy were fatigue (43%
with KEYTRUDA), pruritus (28% vs 8%), rash (24% vs 8%),
constipation (22% vs 20%), nausea (22% with KEYTRUDA), diarrhea
(20% vs 20%), and decreased appetite (20% with KEYTRUDA).
Corresponding incidence rates are listed for chemotherapy only for
those adverse reactions that occurred at the same or lower rate
than with KEYTRUDA.
KEYTRUDA was discontinued due to adverse reactions in 8% of 682
patients with metastatic NSCLC. The most common adverse event
resulting in permanent discontinuation of KEYTRUDA (pembrolizumab)
was pneumonitis (1.8%). Adverse reactions leading to interruption
of KEYTRUDA occurred in 23% of patients; the most common (≥1%) were
diarrhea (1%), fatigue (1.3%), pneumonia (1%), liver enzyme
elevation (1.2%), decreased appetite (1.3%), and pneumonitis (1%).
The most common adverse reactions (occurring in at least 20% of
patients and at a higher incidence than with docetaxel) were
decreased appetite (25% vs 23%), dyspnea (23% vs 20%), and nausea
(20% vs 18%).
KEYTRUDA was discontinued due to adverse reactions in 17% of 192
patients with HNSCC. Serious adverse reactions occurred in 45% of
patients. The most frequent serious adverse reactions reported in
at least 2% of patients were pneumonia, dyspnea, confusional state,
vomiting, pleural effusion, and respiratory failure. The most
common adverse reactions (reported in at least 20% of patients)
were fatigue, decreased appetite, and dyspnea. Adverse reactions
occurring in patients with HNSCC were generally similar to those
occurring in patients with melanoma or NSCLC, with the exception of
increased incidences of facial edema (10% all Grades; 2.1% Grades 3
or 4) and new or worsening hypothyroidism.
It is not known whether KEYTRUDA is excreted in human milk.
Because many drugs are excreted in human milk, instruct women to
discontinue nursing during treatment with KEYTRUDA and for 4 months
after the final dose.
Safety and effectiveness of KEYTRUDA have not been established
in pediatric patients.
Our Focus on Cancer
Our goal is to translate breakthrough science into innovative
oncology medicines to help people with cancer worldwide. At Merck,
helping people fight cancer is our passion and supporting
accessibility to our cancer medicines is our commitment. Our focus
is on pursuing research in immuno-oncology and we are accelerating
every step in the journey – from lab to clinic – to potentially
bring new hope to people with cancer.
As part of our focus on cancer, Merck is committed to exploring
the potential of immuno-oncology with one of the fastest-growing
development programs in the industry. We are currently executing an
expansive research program that includes nearly 400 clinical trials
evaluating our anti-PD-1 therapy across more than 30 tumor types.
We also continue to strengthen our immuno-oncology portfolio
through strategic acquisitions and are prioritizing the development
of several promising immunotherapeutic candidates with the
potential to improve the treatment of advanced cancers.
For more information about our oncology clinical trials, visit
www.merck.com/clinicaltrials.
About Merck
For 125 years, Merck has been a global health care leader
working to help the world be well. Merck is known as MSD outside
the United States and Canada. Through our prescription medicines,
vaccines, biologic therapies, and animal health products, we work
with customers and operate in more than 140 countries to deliver
innovative health solutions. We also demonstrate our commitment to
increasing access to health care through far-reaching policies,
programs and partnerships. For more information, visit
www.merck.com and connect with us on Twitter, Facebook, YouTube and
LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
There can be no guarantees with respect to pipeline products that
the products will receive the necessary regulatory approvals or
that they will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2015
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
Please see Prescribing Information for KEYTRUDA
(pembrolizumab)
at http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf and
Patient Information/Medication Guide for KEYTRUDA
at http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_mg.pdf.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161205006375/en/
MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton,
908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug,
908-740-1898
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024